Search results for "replacement therapy"

showing 10 items of 289 documents

207 Diagnosis of Anderson-Fabry Disease in Childhood. What Should We Focus on?

2004

Background: Anderson-Fabry disease (FD) is an X-linked lysosomal storage disorder which also affects female carriers and has an early onset of symptoms in childhood in both genders. Signs and symptoms are frequently misunderstood and often diagnosis is made approximately 10–20 years after their onset. This has been clearly demonstrated by Fabry outcome survey (FOS) a European database on the natural history of FD and the effects of enzyme replacement therapy with agalsidase alfa (Replagal). Methods: Demographic data on 82 children (40 boys and 42 girls) below 18 years of age, with a median age at FOS entry of 12.9 (0.7–17.9) were analysed Results: Most frequently reported symptoms (60–80%) …

Abdominal painPediatricsmedicine.medical_specialtybiologybusiness.industryEnzyme replacement therapyDiseasemedicine.diseasebiology.organism_classificationAngiokeratomaNatural historyAnderson-Fabry DiseaseVertigoPediatrics Perinatology and Child Healthmedicinemedicine.symptombusinessTinnitusPediatric Research
researchProduct

Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy

2003

Abstract Purpose Recurrent angioedema, characterized by skin swelling, colicky attacks of abdominal pain, and life-threatening laryngeal edema, can be either hereditary or acquired. According to anecdotal reports, it may be associated with use of oral contraceptives and hormone replacement therapy. We investigated potential interactions between these medications and various types of recurrent angioedema in a large cohort of women. Methods Women with recurrent angioedema (n = 516) underwent a thorough medical evaluation. They were then classified by type of angioedema, using standard criteria. Results Of the 516 women, 228 (44%) had used oral contraceptives or hormone replacement therapy, in…

AdultAbdominal painmedicine.medical_specialtyHormone Replacement TherapyPopulationRisk AssessmentSeverity of Illness IndexCohort StudiesAge DistributionRecurrenceimmune system diseasesHumansMedicineHereditary Angioedema Type IIIcardiovascular diseasesAngioedemaRisk factorskin and connective tissue diseaseseducationAgedRetrospective Studieseducation.field_of_studyAngioedemabusiness.industryfood and beveragesRetrospective cohort studyGeneral MedicineMiddle AgedPrognosisDermatologyAbdominal PainSurgeryTransgender hormone therapyFemalemedicine.symptombusinessComplicationContraceptives OralThe American Journal of Medicine
researchProduct

The influence of apo E phenotypes on the plasma triglycerides response to hormonal replacement therapy during the menopause

2001

Objective: To study the influence of apo E phenotype in plasma lipids, especially in triglycerides levels, in menopausal women receiving hormonal replacement therapy (HRT). Methods: One hundred and ten postmenopausal women were studied. Plasma total cholesterol (TC), HDL-C and triglycerides (TG) were measured before and after 3 months of HRT and the apo E phenotype was determined. According to the apo E phenotype the sample was divided into three groups: E2/E3 (n=28), E3/E3 (n=96) and E4/E3 (n=25). Results: In the pre-treatment state, higher plasma levels of TC and TC/HDL-C ratio were observed in women with phenotype E3/E4 (P<0.0001 and P<0.02, respectively), while higher plasma TG levels w…

AdultApolipoprotein EMedroxyprogesteronemedicine.medical_specialtyHormone Replacement Therapymedicine.drug_classmedicine.medical_treatmentAdministration OralAdministration CutaneousWhite PeopleGeneral Biochemistry Genetics and Molecular BiologyCohort StudiesApolipoproteins EPolymorphism (computer science)Internal medicinemedicineHumansProspective StudiesTriglyceridesChemotherapyEstradiolbusiness.industryCholesterol HDLHormonal replacement therapyObstetrics and GynecologyMiddle Agedmedicine.diseasePhenotypeMenopauseCholesterolPhenotypeEndocrinologyCardiovascular DiseasesSpainEstrogenFemaleMenopausebusinessPharmacogeneticsMaturitas
researchProduct

The effect of growth hormone ( GH ) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency: real‐life data from th…

2015

SummaryObjective To assess the effect of 4 years’ growth hormone (GH) replacement on glucose homeostasis and evaluate factors affecting glycosylated haemoglobin (HbA1c) in adults with growth hormone deficiency (GHD). Design NordiNet® International Outcome Study, a noninterventional study, monitors long-term effectiveness and safety of GH replacement [Norditropin® (somatropin), Novo Nordisk A/S] in real-life clinical practice. Patients Nondiabetic patients (n = 245) with adult-onset GHD (age ≥20 years at GH start), ≥4 years’ GH replacement and HbA1c values at baseline and 4 years were included in the analysis. Measurements Changes from baseline (∆) to 4 years in HbA1c, fasting plasma glucose…

AdultBlood GlucoseMalemedicine.medical_specialtyWaistendocrine system diseasesHormone Replacement TherapyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematologyGrowth hormone deficiencyImpaired glucose toleranceYoung Adult03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineDiabetes mellitusDiabetes MellitusmedicineHomeostasisHumansGlucose homeostasisYoung adultAgedAged 80 and overGlycated Hemoglobinbusiness.industrynutritional and metabolic diseasesMiddle Agedmedicine.diseaseSomatropinTreatment OutcomeEndocrinologyGrowth HormoneFemalebusinessBody mass indexClinical Endocrinology
researchProduct

Hormone therapy is associated with better body composition and adipokine/glucose profiles

2012

Objective: The aim of this study was to evaluate the possibility of preventing the metabolic health consequences of postmenopausal hypogonadism with the use of long-term hormone therapy (HT). Methods: We used a monozygotic co-twin control design including 10 twin pairs (aged 56-62 y) discordant for HT (duration of HT, 2-10 y). In addition, 14 premenopausal women (aged 29-35 y) who did not use HT were studied to evaluate the differences in metabolic health between the premenopausal and postmenopausal states. Body composition was determined, and waist-to-hip ratio was used as an estimate for fat distribution. Serum sex steroids, sex hormone-binding globulin, and serum lipid and glucose profil…

AdultBlood Glucosenaisetmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentkehon koostumusCo twin controlAdipose tissueAdipokineCarbohydrate metabolismAdipokinesSex Hormone-Binding GlobulinInternal medicineLeukocytesmedicineHumansRNA MessengerGonadal Steroid HormonesMuscle SkeletalChemokine CCL2kehonkoostumusMetabolic healthkaksostutkimusWaist-Hip Ratiobusiness.industryEstrogen Replacement TherapyadipokoinesObstetrics and Gynecologyta3141Twin studyTwins MonozygoticMiddle Agedadipokiinitmedicine.diseaseLipidsPostmenopauseMenopauseEndocrinologyAdipose TissuePremenopauseEstrogenCase-Control StudiesBody CompositionFemaleHormone therapyInsulin ResistancebusinessMenopause
researchProduct

AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement.

2020

Lysosomal storage diseases (LSDs) are a heterogeneous group of inherited disorders caused by loss-of-function mutations in genes encoding for lysosomal enzymes/proteins. The consequence is a progressive accumulation of substrates in these intracellular organelles, resulting in cellular and tissue damage. The overall incidence is about 1/8000 live births, but is likely underestimated. LSDs are chronic progressive multi-systemic disorders, generally presenting with visceromegaly, and involvement of the central nervous system, eyes, the skeleton, and the respiratory and cardiovascular systems. The age at onset and phenotypic expression are highly variable, according to the specific enzymatic d…

AdultHepatosplenomegalyLysosomal acid lipase deficiencyBioinformaticsOrganomegaly03 medical and health sciencesLiver disease0302 clinical medicinemedicineCholesteryl ester storage disease Enzyme replacement therapy Gaucher disease Lysosomal acid lipase Niemann–Pick disease deficiency Substrate reduction therapyHumansSubstrate reduction therapyEnzyme Replacement TherapySocieties MedicalNiemann-Pick DiseasesAcid sphingomyelinase deficiencyGaucher DiseaseHepatologybusiness.industryGastroenterologyWolman DiseaseEnzyme replacement therapymedicine.diseaseLysosomal Storage DiseasesSphingomyelin PhosphodiesteraseItaly030220 oncology & carcinogenesis030211 gastroenterology & hepatologymedicine.symptombusinessNiemann–Pick diseaseLysosomesVisceromegalyDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Physiological Estrogen Replacement May Enhance the Effectiveness of the Gonadotropin-Releasing Hormone Agonist in the Treatment of Hirsutism

1994

GnRH agonists (GnRH-A) have been used for the treatment of hirsutism in women with ovarian hyperandrogenism. However, significant side-effects, including vasomotor symptoms and bone loss, have prevented the long term use of this therapy. In this study, we evaluated the effects of low dose (physiological) estrogen replacement on the side-effects and clinical and hormonal parameters of 22 hirsute women with ovarian hyperandrogenism when treated with a long-acting GnRH-A, Decapeptyl. Ten patients with Ferriman-Gallwey (FG) scores averaging 13.4 +/- 1.5 were randomly assigned to be treated with Decapeptyl alone (3.75 mg, im, every 28 days for 6 months), and 12 other patients with FG scores aver…

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryOvaryMedroxyprogesterone AcetateGonadotropin-releasing hormoneBiochemistryGonadotropin-Releasing HormoneEndocrinologyGonadotropin-releasing hormone agonistInternal medicinemedicineHumansMedroxyprogesterone acetateEstrogen replacementConjugated Equine EstrogensTestosteronehirsutismTriptorelin PamoateVasomotorbusiness.industryEstrogen Replacement TherapyBiochemistry (medical)HyperandrogenismObstetrics and GynecologyDrug SynergismGeneral Medicinemedicine.diseaseMenstruationmedicine.anatomical_structureEndocrinologyEstrogenGonadotropins PituitaryAndrogensDrug Therapy CombinationFemalebusinesshormones hormone substitutes and hormone antagonistsHormonemedicine.drugObstetrical &amp; Gynecological Survey
researchProduct

Gastrointestinal disturbances and their management in miglustat‐treated patients

2011

Miglustat (Zavesca®) is approved for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease (GD1) for whom enzyme replacement therapy is unsuitable, and for the treatment of progressive neurological manifestations in adult and paediatric patients with Niemann-Pick disease type C (NP-C). Gastrointestinal disturbances such as diarrhoea, flatulence and abdominal pain/discomfort have consistently been reported as the most frequent adverse events associated with miglustat during clinical trials and in real-world clinical practice settings. These adverse events are generally mild or moderate in severity, occurring mostly during the initial weeks of therapy. The mechanis…

AdultLoperamideAbdominal painmedicine.medical_specialty1-DeoxynojirimycinMalabsorptionDrug-Related Side Effects and Adverse ReactionsGastrointestinal DiseasesModels BiologicalGastroenterologyInternal medicineMiglustatGeneticsmedicineHumansEnzyme InhibitorsChildAdverse effectGenetics (clinical)Clinical Trials as TopicGaucher Diseasebusiness.industryEnzyme replacement therapymedicine.diseaseClinical trialEndocrinologymedicine.symptombusinessFlatulencemedicine.drugJournal of Inherited Metabolic Disease
researchProduct

Cholelithiasis in Patients with Gaucher Disease type 1: Risk Factors and the Role of ABCG5/ABCG8 Gene Variants

2016

Background &amp; Aim: Patients with Gaucher disease type 1 (GD1) show an altered lipid profile and a certain degree of insulin resistance, which might contribute to cholelithiasis (CL) and could possibly be associated with ABCG5/ABCG8 gene variants. We aimed to investigate the prevalence of CL in Caucasian adult patients with GD1 and the possible risk factors, including gene variants of the ABCG5/ABCG8 genes.&#x0D; Methods: 61 Caucasian patients with GD1 (38 female/23male), aged 18-62 years and 61 healthy subjects matched for age, gender and BMI, without CL, for comparison of lipid profiles. Data before start of enzyme replacement therapy (ERT) were recorded: clinical, haematological, sever…

AdultMale0301 basic medicineHeterozygotemedicine.medical_specialtyAdolescentLipoproteinsmedicine.medical_treatmentSplenectomyABCG8030105 genetics & heredityGastroenterologyWhite PeopleYoung Adult03 medical and health sciencesInsulin resistanceGene FrequencyCholelithiasisRisk FactorsInternal medicineGenotypePrevalencemedicineHumansEnzyme Replacement TherapyGenetic Predisposition to DiseaseATP Binding Cassette Transporter Subfamily G Member 5Genetic Association StudiesGaucher Diseasemedicine.diagnostic_testRomaniabusiness.industryATP Binding Cassette Transporter Subfamily G Member 8HomozygoteGastroenterologyCase-control studyGenetic VariationEnzyme replacement therapyMiddle Agedmedicine.diseaseCross-Sectional StudiesPhenotypeCase-Control StudiesGlucosylceramidaseFemaleLipid profilebusinessDyslipidemiaJournal of Gastrointestinal and Liver Diseases
researchProduct

Growth hormone replacement in adults:Real-world data from two large studies in US and Europe

2020

Objective: This report describes the effectiveness and safety of growth hormone replacement in 3180 adult patients with growth hormone deficiency followed-up for 0.0–12.2 years in two completed, complementary, non-interventional, multicentre studies, NordiNet® International Outcome Study (IOS) (NCT00960128) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program (NCT01009905). Design: In both studies, Norditropin® (somatropin; Novo Nordisk A/S, Denmark) was administered at the discretion of the treating physician and according to routine practice. We present data on baseline characteristics, growth hormone dose, safety data and change from baseline in waist circumferenc…

AdultMale0301 basic medicineIGF-I SDSPediatricsmedicine.medical_specialtyWaistHormone Replacement TherapyEndocrinology Diabetes and MetabolismANSWER Program030209 endocrinology & metabolismEffectivenessGrowth hormoneNordiNet® International Outcome Study (IOS)Body compositionHypopituitarismBody Mass IndexGrowth hormone deficiency03 medical and health sciences0302 clinical medicineEndocrinologyElectric ImpedancemedicineHumansGrowth hormone replacementAgedAdult patientsHuman Growth Hormonebusiness.industryMiddle Agedmedicine.diseaseRecombinant ProteinsUnited StatesReal-world dataEuropeClinical Practice030104 developmental biologyGrowth hormone deficiency in adultsBaseline characteristicsBody CompositionFemaleWaist CircumferenceSafetybusinessReal world dataBody mass index
researchProduct